Ovid Therapeutics Inc (OVID.OQ)
9.98USD
20 Apr 2018
$-0.16 (-1.58%)
$10.14
$10.36
$10.41
$9.80
22,636
28,657
$15.70
$5.28
Latest Key Developments (Source: Significant Developments)
Ovid Therapeutics Announces OV101 Granted Fast Track Designation By FDA For Fragile X Syndrome Treatment
March 15 (Reuters) - Ovid Therapeutics Inc
Ovid Therapeutics Announces TAK-935/OV935 Granted Orphan Drug Designation By U.S. FDA For Treatment Of Lennox-Gastaut Syndrome
Dec 20 (Reuters) - Ovid Therapeutics Inc
Ovid Therapeutics Announces OV101 Granted Fast Track Designation By U.S. FDA For Treatment Of Angelman Syndrome
Dec 19 (Reuters) - Ovid Therapeutics Inc
Ovid Therapeutics Announces TAK-935/Ov935 Has Received Orphan Drug Designation From U.S. FDA For Treatment Of Dravet Syndrome
Dec 5 (Reuters) - Ovid Therapeutics Inc
Ovid Therapeutics Announces OV101 Shows Comparable Pk Profile In Phase 1 Study Of Adolescent Patients
Nov 28 (Reuters) - Ovid Therapeutics Inc
Ovid Therapeutics Q3 loss per share $0.38
Nov 9 (Reuters) - Ovid Therapeutics Inc
Ovid Therapeutics Q2 loss per share $0.57
Aug 10 (Reuters) - Ovid Therapeutics Inc
Ovid Therapeutics shares open at $14.00 in debut, 6.7 pct below IPO price
May 5 (Reuters) - :Ovid Therapeutics Inc shares open at $14.00 in debut, below IPO price of $15.00 per share. Full Article
Ovid Therapeutics prices 5 mln share offering at $15 per share
May 4 (Reuters) - Ovid Therapeutics Inc
BRIEF-Ovid Therapeutics Reports Q4 Loss Per Share $0.45
* OVID THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND CORPORATE PROGRESS